Fagron Advanced Derma
Perspectives on the safety and tolerance of topical ingredients have changed dramatically as a result of advanced research-driven knowledge. Fagron Advanced Derma is the global standard for advanced individual dermatological care and offers solutions that are derived from the latest scientific knowledge of dermatology. With the range of highly compatible vehicles, compounding formulations and stability studies, prescribers and pharmacists can offer their patients customized treatment based on indication and skin conditions. To minimize skin irritation, long-term adverse reactions and allergies, Fagron Advanced Derma vehicles are designed to be free of harmful, obsolete and controversial ingredients. The careful selection of ingredients has resulted in vehicles that can be safely used by all patients – even babies, children, pregnant women and the elderly.
Latanoprost is used clinically as an eye drops solution for the treatment of open angle glaucoma and ocular hypertension. Increased growth and pigmentation, additional lash rows and thickness of eyelashes are reported side effects of Latanoprost eye drops. Numerous studies with positive results have been published on the efficacy of Latanoprost in the treatment of eyelash alopecia. Worldwide, there is a lack of effective products for hair growth and eyelash growth.
Fagron has researched and developed formulations that allow dermatologists and compounding pharmacists to deliver their patient an effective customized treatment for (eyelash) alopecia based on Latanoprost in Fagron vehicles.
Topical application of coal tar is an effective therapy for reducing inflammation and itch in atopic dermatitis and psoriasis. It has been used to treat skin diseases for more than 2000 years. However, the smell, color and safety profile of coal tar preparations are to be improved.
In collaboration with the Department of Dermatology at the Radboud University Medical Centre, Fagron is researching the development of a coal tar preparation that should have superior qualities over existing coal tar preparations. This will significantly improve patient comfort and thus patience compliance and therapeutic outcomes. Through pharmaceutical compounding, prescribers and pharmacists can improve the quality of life of patients with atopic dermatitis and psoriasis. Results of this promising research project are expected in 2017.